NEW YORK (GenomeWeb) – Quest Diagnostics today reported that its first quarter sales declined around 2 percent year over year with reimbursement issues and an "unseasonably harsh winter" cited as factors for the decrease.

The Madison, NJ-based clinical lab and diagnostic information services firm reported revenues from continuing operations of $1.75 billion, down from $1.79 billion in the first quarter of 2013. It matched the consensus Wall Street estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.